The Personalized NSAID Therapeutics Consortium (PENTACON) is a group of 42 scientists from 22 institutions who have decided to test whether a paradigm for the personalization of drug treatment can be successfully developed. They have applied for funding through the National Institute of General Medical Sciences (NIGMS) GLUE grant mechanism.
PENTACON scientists approach the challenge of personalizing chronic drug therapy by focusing on a single class of drugs – nonsteroidal anti-inflammatory drugs (NSAIDs), initially exploring in detail what factors might contribute to variability in drug response and how that might be reflected by quantitative assays that might predict efficacy or risk.
This involves two major challenges; firstly, the attempt to integrate heterogeneous data – genomics, epigenomics, proteomics, lipidomics, imaging, metabolomics and microbiomics and secondly, the integration of such data from 5 systems – yeast, mammalian cells, zebrafish, mice and humans.
The null hypothesis is that harnessing such information will NOT allow us to provide incremental value to physicians as they decide whether to put a patient on an NSAID and if so which one, at what dose and for how long.
If this hypothesis is rejected for NSAIDs, it will afford a completely novel paradigm for the personalization of medicine.